Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended ...

U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Volpara Health, a Lunit a company and global leader in software for the early detection of breast cancer, today applauded the significant advancement in breast health management with BreastScreen ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating ...